Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

June 7, 2017June 7, 2017

SIR-Spheres Radiation Microspheres Outperform Chemo in Liver Cancer Trial

News

SIR-Spheres radiation microspheres shrank the tumors of a significantly larger number of liver cancer patients than the standard-of-care chemotherapy Nexavar (sorafenib), according to a Phase 3 clinical trial. The microspheres, which Sirtex ... Read more

May 18, 2017May 18, 2017

Albireo Wins 2 U.S. Patents for A4250 Therapy to Treat NASH, Other Liver Diseases

Cholestasis, News, Non-alcoholic steatohepatitis

Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Boston-based Albireo has reported promising preclinical ... Read more

May 17, 2017May 17, 2017

Monkey Studies Prove Safety, Tolerability of IVA337 Experimental Therapy for Non-alcoholic Steatohepatitis

News, Non-alcoholic steatohepatitis

Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in monkeys, according to a 12-month non-human primate toxicology ... Read more

May 2, 2017May 12, 2017

New Study Is Examining How Doctors Manage Patients with Liver Disease

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A large observational study is looking at how doctors manage people with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFL). TARGET PharmaSolutions is conducting the study in collaboration with the biopharmaceutical company Allergan. ... Read more

April 13, 2017April 19, 2017

Bozitinib Suppresses Liver Tumor Growth in Lab Setting, Study Shows

Liver cancer, News

Bozitinib (CBT-101) suppresses the growth of human liver tumors in a laboratory environment, according to its maker, CBT Pharmaceuticals. The oral therapy works by targeting a faulty protein signaling pathway that ... Read more

April 11, 2017April 11, 2017

Conatus Discusses Its Liver Disease Therapy Emricasan at Two New York Events

Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Conatus Pharmaceuticals updated participants at two New York medical conferences this month on its efforts to develop emricasan, which has been shown to improve manifestations of chronic kidney disease. The San Diego-based ... Read more

March 30, 2017April 5, 2017

CymaBay Continues Development of Seladelpar for Liver Disease as Interim President, CEO Named

News, Non-alcoholic steatohepatitis

CymaBay Therapeutics has named Sujal Shah as interim president and CEO following the retirement of Harold Van Wart, PhD. Robert Wills, PhD, will serve as executive chairman during this transition phase. California-based ... Read more